Wellington Management Group LLP Invests $675,000 in Aldeyra Therapeutics, Inc. $ALDX

Wellington Management Group LLP purchased a new position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 117,475 shares of the biotechnology company's stock, valued at approximately $675,000. Wellington Management Group LLP owned about 0.20% of Aldeyra Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC bought a new position in shares of Aldeyra Therapeutics during the 1st quarter valued at $63,000. Hsbc Holdings PLC bought a new position in shares of Aldeyra Therapeutics during the 4th quarter valued at $52,000. Millennium Management LLC bought a new position in shares of Aldeyra Therapeutics during the 4th quarter valued at $808,000. Mackenzie Financial Corp grew its holdings in shares of Aldeyra Therapeutics by 310.9% during the 4th quarter. Mackenzie Financial Corp now owns 47,792 shares of the biotechnology company's stock valued at $238,000 after purchasing an additional 36,160 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Aldeyra Therapeutics by 1,575.7% during the 1st quarter. Invesco Ltd. now owns 501,137 shares of the biotechnology company's stock valued at $2,882,000 after purchasing an additional 471,231 shares during the last quarter. Institutional investors own 59.71% of the company's stock.

Insider Activity at Aldeyra Therapeutics

In other news, insider Stephen Machatha sold 22,073 shares of the firm's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $5.15, for a total value of $113,675.95. Following the completion of the sale, the insider directly owned 221,799 shares of the company's stock, valued at approximately $1,142,264.85. This trade represents a 9.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 9.60% of the company's stock.

Aldeyra Therapeutics Price Performance

Aldeyra Therapeutics stock traded up $0.03 during trading hours on Friday, reaching $5.56. The stock had a trading volume of 1,063,041 shares, compared to its average volume of 769,846. The stock has a market cap of $333.04 million, a PE ratio of -6.54 and a beta of 0.80. Aldeyra Therapeutics, Inc. has a 52 week low of $1.14 and a 52 week high of $7.20. The company has a fifty day simple moving average of $5.19 and a 200-day simple moving average of $4.22.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.05. Research analysts predict that Aldeyra Therapeutics, Inc. will post -0.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ALDX has been the topic of several recent research reports. Zacks Research raised shares of Aldeyra Therapeutics to a "hold" rating in a report on Friday, August 8th. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a report on Monday, May 19th. Finally, Wall Street Zen raised shares of Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 21st. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.50.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.